Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia Clinical Trial
Determination of the maximum tolerated dose (MTD) of fractionated RIT with epratuzumab radiolabeled with yttrium-90 (90Y-epratuzumab) preceding a reduced conditioning regimen FB2A2 before allogeneic stem cell transplantation.
- Physical examination (screening and follow-up)
- Complete blood counts (screening and follow-up)
- Dosage of FLT3-ligand in plasma (screening and follow-up)
- Blood ionogramme, creatinine hepatic work-up (screening and follow-up)
- Left ventricular ejection fraction at pre-implant assessment
- Immunization test (screening and follow-up)
- Bone marrow aspiration or/and blood CD 22 immunophenotype for minimal residual disease
evaluation (screening and follow-up)
- All exams which were initially abnormal and which are necessary for response evaluation
and All exams which are needed in case of relapse suspicion.
- Pharmacokinetic of 90Y-hLL2
;